Crude and age-specific incidence rate patterns for histopathologic subtypes of ovarian cancer in Iran

The purpose of this study was to report age-specific incidence rates of histopathological subtypes of ovarian cancer in Iran. Data published by the pathology-based Cancer Registry, Iranian Ministry of Health and Medical Education for the year 2004, was utilized. This study included 793 new ovarian cancer cases which were analyzed by SPSS software [version 13]. There were 45 different histologies reported in 793 new cases which were categorized into ten major groups. Epithelial tumors displayed the highest age specific incidence rate, followed by germ cell tumors. Serous epithelial tumors were the most common in the epithelial group. The age-specific incidence rate of ovarian cancer varies based on histolo

[Conventional chemoradiation with cisplatin versus hemoradiation with cisplatin plus gemcitabine in uterine cervical cancer]

Due to high mortality and morbidity of the cervical cancer we decided to compare benefits and advers effects of Gemcitabine plus conventional chemoradiation with conventional chemoradiation with cisplatin alone in Imam Hossein hospital, in Tehran, Iran. This double blind clinical trial, was carried out on 34 patients with documented cervical carcinoma during 2006-07 the patients divided into two sub groups: [A]Conventional concurrent chemoradiation with cisplatin[N=18] versus[B] concurrent chemoradiation with cisplatin plus gemicitabine [N=16]. The patients with clinical stage of IB2-IVA and normal cell blood count with normal renal and liver function tests included in the study. Irradiation was delivered to all patients through external and internal beams with same dose and schedule. The patients followed for 3 months at least. Clinical response rate and adverse events included Neutropenin, Thrombocytopenia, anemia, diarrhea, nausea, and vomiting compared in two groups with fisher exact test, and t-test Despite increasing of complete response rate with adding gemcitabine to conventional treatment[81.2% vs. 66.7%], the difference in two groups was not statistically significant. This study indicated that the addition of gemicatabine to conventional chemoradiation with cisplatinrevealed no significant benefits. All adverse events in combination chemotherapy group were greater than conventional treatment